Cellbxhealth Plc · LSE:CLBX
Cellbxhealth — ANGLE — Investor Presentation (October 2011)
10 slides from Cellbxhealth's investor presentation, Oct 7, 2011
Slide 1: An Introduction to PARSORTIX
An Introduction to PARSORTIX Presented by: Andrew Newland, Chief Executive Shane Booth, CEO, Parsortix 7 October 2011
Slide 2: Parsortix: Patented technology for separating rare cells from blood
Major medical diagnostic development for ANGLE Parsortix Patented technology for separating rare cells from blood Forward-Looking Statements This presentation and the associated commentary contains certain forward-looking statements based on current expectations, forecasts and assumptions that invol
Slide 3: Market for circulating tumour cell (CTC) separation device
Market for circulating tumour cell (CTC) separation device Use of CTC cell counting (simple product) for: − Research product (does not need regulatory approval) − Monitoring patient response to chemotherapy − Monitoring patients in remission to identify CTC ahead of secondary tumours 1.2 million new
Slide 4: Parsortix: separation cassette schematic
Parsortix: separation cassette schematic Cassette components Fully assembled cassette Cassette housing © ANGLE plc 2011 Page 4
Slide 5: Captured cells: whole blood control and spiked with SK-Br-3
Captured cells: whole blood control and spiked with SK-Br-3 Control Spiked with breast cancer cells © ANGLE plc 2011 Page 5
Slide 6: Chromogenic staining of SK-Br-3 cells
Chromogenic staining of SK-Br-3 cells Stained breast Cancer cells Visual ID breast cancer cells Identified cells marked using cytokeratin-18 © ANGLE plc 2011
Slide 7: Development Plan
Development Plan Finalise work on characterising the separation device including flow and volume capability Finalise market requirements for device Optimise design of separation device (next generation) Establish collaboration with cancer research centre(s) Separation of CTCs from cancer patient blo
Slide 8: Newsflow potential
Newsflow potential Quarter ended 31-Oct-11 31-Jan-12 30-Apr-12 31-Jul-12 31-Oct-12 31-Jan-13 30-Apr-13 31-Jul-13 Continue and expand sales for research purposes Establish Optimise Initiate sales collaborative separation for research Comparative studies to support FDA and CE Mark research with casset
Slide 9: Near-term commercial potential
Near-term commercial potential Target sales launch of product for research purposes mid 2012 − No requirement for regulatory approval − Immediate market potential − Astra Zeneca 20,000 separations p.a. with one research lab − Early sales potential $25m p.a. Target FDA approval of product for clinica
Slide 10: Legal disclaimer
Legal disclaimer The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment (without notice), verification and completeness. This document is being supplied to you solely for your information and may not be reproduced, redistributed or